Payment overview · 2025
General Payments
$975.62
48 reported records · 12 companies
Healthcare provider profile · identity verified
Wesley Robert Hanson, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROAN MOUNTAIN, TN · NPI 1104821743
Verified facts
What the public records show
CMS Open Payments records show Wesley Robert Hanson, MD received $975.62 in general payments during 2025 across 48 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $294.58 | 30.2% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $257.13 | 26.4% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $134.34 | 13.8% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.34 | 5.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.41 | 5.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.19 | 4.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.94 | 3.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $29.27 | 3.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.07 | 2.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.81 | 2.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.17 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.37 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $859.62 | 47 |
| Education | $116.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $247.77 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $179.02 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $134.34 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.36 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $78.11 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $74.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.34 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.41 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.19 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $29.27 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.50 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 16 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 105 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 249 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
105 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
249 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 545 | 124 |
| Gabapentin | Gabapentin | 536 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 494 | 136 |
| Omeprazole | Omeprazole | 430 | 109 |
| Lisinopril | Lisinopril | 428 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 108 |
| Furosemide | Furosemide | 330 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 79 |
| Losartan Potassium | Losartan Potassium | 301 | 77 |
| Alprazolam | Alprazolam | 294 | 36 |
| Ozempic | Semaglutide | 249 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 247 | 63 |
| Potassium Chloride | Potassium Chloride | 242 | 67 |
| Metformin Hcl | Metformin Hcl | 239 | 67 |
| Trazodone Hcl | Trazodone Hcl | 233 | 63 |
| Montelukast Sodium | Montelukast Sodium | 206 | 54 |
| Tramadol Hcl | Tramadol Hcl | 203 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 60 |
| Clonazepam | Clonazepam | 199 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 182 | 45 |
| Baclofen | Baclofen | 164 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 46 |
| Spironolactone | Spironolactone | 153 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 42 |
| Carvedilol | Carvedilol | 149 | 34 |
| Meloxicam | Meloxicam | 148 | 53 |
| Lorazepam | Lorazepam | 143 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 38 |
| Buspirone Hcl | Buspirone Hcl | 139 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 41 |
| Famotidine | Famotidine | 138 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | 27 |
| Glimepiride | Glimepiride | 125 | 34 |
| Pregabalin | Pregabalin | 118 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 34 |
| Allopurinol | Allopurinol | 107 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 37 |
| Farxiga | Dapagliflozin Propanediol | 105 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 28 |
| Ibuprofen | Ibuprofen | 104 | 26 |
| Amoxicillin | Amoxicillin | 99 | 69 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 94 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 89 | 20 |
| Azithromycin | Azithromycin | 85 | 55 |
| Sertraline Hcl | Sertraline Hcl | 85 | 25 |
| Eliquis | Apixaban | 84 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 16 |
| Jardiance | Empagliflozin | 73 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 15 |
| Donepezil Hcl | Donepezil Hcl | 71 | 19 |
| Celecoxib | Celecoxib | 70 | 21 |
| Lovastatin | Lovastatin | 69 | 17 |
| Finasteride | Finasteride | 67 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 17 |
| Alendronate Sodium | Alendronate Sodium | 66 | 17 |
| Atenolol | Atenolol | 62 | 17 |
| Fluconazole | Fluconazole | 62 | 32 |
| Promethazine Hcl | Promethazine Hcl | 57 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 54 | 11 |
| Linzess | Linaclotide | 52 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 13 |
| Methylprednisolone | Methylprednisolone | 50 | 33 |
| Simvastatin | Simvastatin | 50 | 13 |
| Temazepam | Temazepam | 49 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 18 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 48 | 37 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Levofloxacin | Levofloxacin | 47 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Estradiol | Estradiol | 45 | 12 |
| Clonidine Hcl | Clonidine Hcl | 44 | 12 |
| Chlorthalidone | Chlorthalidone | 41 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | 13 |
| Nystatin | Nystatin | 38 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | 13 |
| Cefdinir | Cefdinir | 35 | 20 |
| Torsemide | Torsemide | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 16 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 13 |
| Meclizine Hcl | Meclizine Hcl | 31 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 18 |
| Valsartan | Valsartan | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 12 |
| Febuxostat | Febuxostat | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 13 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 17 |
| Digoxin | Digoxin | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | 11 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $975.62 · 48 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, ELIQUIS, FARXIGA, GARDASIL 9, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, VAXNEUVANCE, VRAYLAR, Wegovy, YUPELRI, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error